

Table S2. Overview of the positive and negative antibody status for all the study participants.

	Overall					
	Total number of subjects	missing	% missing		n	%
<b>antiTg</b>	212	83	39.2	<b>Negative</b>	119	92.2
				<b>Positive</b>	10	7.8
<b>antiTPO</b>	212	73	34.4	<b>Negative</b>	108	77.7
				<b>Positive</b>	31	22.3
<b>Cases</b>						
<b>antiTg</b>	106	39	36.8	<b>Negative</b>	84	95.5
				<b>Positive</b>	3	4.5
<b>antiTPO</b>	106	32	30.2	<b>Negative</b>	62	83.8
				<b>Positive</b>	12	16.2
<b>Controls</b>						
<b>antiTg</b>	106	44	41.5	<b>Negative</b>	55	88.7
				<b>Positive</b>	7	11.3
<b>antiTPO</b>	106	41	38.7	<b>Negative</b>	46	70.8
				<b>Positive</b>	19	29.2
<b>Cyprus</b>						
	Total number of subjects	Missing	% missing		n	%
<b>antiTg</b>	122	63	51.6	<b>Negative</b>	56	94.9
				<b>Positive</b>	3	5.1
<b>antiTPO</b>	122	61	50	<b>Negative</b>	52	85.2
				<b>Positive</b>	9	14.8
<b>Cyprus</b>						
	Cases	Missing	% missing		n	%
<b>antiTg</b>	57	30	52.6	<b>Negative</b>	26	96.3
				<b>Positive</b>	1	3.7
<b>antiTPO</b>	57	28	49.1	<b>Negative</b>	28	96.6
				<b>Positive</b>	1	3.4
<b>Controls</b>						
	Missing	% missing		n	%	
<b>antiTg</b>	65	33	50.8	<b>Negative</b>	30	93.8
				<b>Positive</b>	2	6.2
<b>antiTPO</b>	65	33	50.8	<b>Negative</b>	24	75.0
				<b>Positive</b>	8	25.0
<b>Romania</b>						
	Total number of subjects	missing	% missing		n	%
<b>antiTg</b>	90	20	22.2	<b>Negative</b>	63	90

				<b>Positive</b>	7	10
<b>antiTPO</b>	90	12	13.3	<b>Negative</b>	56	71.8
				<b>Positive</b>	22	28.2
	<b>Cases</b>				<i>n</i>	<b>%</b>
<b>antiTg</b>	49	9	18.4	<b>Negative</b>	38	95
				<b>Positive</b>	2	5
<b>antiTPO</b>	49	4	8.2	<b>Negative</b>	34	75.6
				<b>Positive</b>	11	24.4
	<b>Controls</b>				<i>n</i>	<b>%</b>
<b>antiTg</b>	41	11	26.8	<b>Negative</b>	25	83.3
				<b>Positive</b>	5	16.7
<b>antiTPO</b>	41	8	19.5	<b>Negative</b>	22	66.7
				<b>Positive</b>	11	33.3